Nesvategrast (OTT166) in Diabetic Retinopathy (DR)

PHASE2CompletedINTERVENTIONAL
Enrollment

225

Participants

Timeline

Start Date

July 29, 2022

Primary Completion Date

December 29, 2023

Study Completion Date

December 29, 2023

Conditions
Diabetic Retinopathy
Interventions
DRUG

OTT166

Participants will receive OTT166 ophthalmic solution

DRUG

Vehicle control

Participants will receive vehicle control

Trial Locations (68)

13088

Clinical Site 109, Liverpool

14618

Clinical Site 162, Rochester

18704

Clinical Site 115, Kingston

21237

Clinical Site 163, Baltimore

21287

Clinical Site 145, Baltimore

21740

Clinical Site 103, Hagerstown

24502

Clinical Site 159, Lynchburg

27587

Clinical Site 165, Raleigh

29902

Clinical Site 130, Beaufort

32216

Clinical Site 131, Jacksonville

33067

Clinical Site 157, Coral Springs

33143

Clinical Site 110, Miami

33309

Clinical Site 106, Fort Lauderdale

33880

Clinical Site 117, Winter Haven

37203

Clinical Site 119, Nashville

38119

Clinical Site 169, Memphis

38138

Clinical Site 168, Germantown

38671

Clinical Site 155, Southaven

40206

Clinical Site 166, Louisville

43016

Clinical Site 152, Dublin

44122

Clinical Site 143, Beachwood

Clinical Site 120, Cleveland

48201

Clinical Site 141, Detroit

57701

Clinical Site 133, Rapid City

60452

Clinical Site 146, Oak Forest

62704

Clinical Site 128, Springfield

66215

Clinical Site 139, Lenexa

70006

Clinical Site 167, Metairie

73013

Clinical Site 122, Edmond

76028

Clinical Site 147, Burleson

76104

Clinical Site 132, Fort Worth

77025

Clinical Site 156, Houston

77401

Clinical Site 102, Bellaire

Clinical Site 108, Bellaire

78240

Clinical Site 137, San Antonio

Clinical Site 144, Texas City

78503

Clinical Site 126, McAllen

78705

Clinical Site 161, Austin

85021

Clinical Site 150, Phoenix

85381

Clinical Site 123, Peoria

87109

Clinical Site 118, Albuquerque

89502

Clinical Site 101, Reno

90211

Clinical Site 111, Beverly Hills

90505

CinCor Site 171, Torrance

91105

Clinical Site 121, Pasadena

91107

Clinical Site 127, Pasadena

91436

Clinical Site 113, Encino

92505

Clinical Site 116, Riverside

92647

Clinical Site 129, Huntington Beach

93720

Clinical Site 138, Fresno

95670

Clinical Site 142, Rancho Cordova

95841

Clinical Site 125, Sacramento

96701

Clinical Site 112, ‘Aiea

97239

Clinical Site 135, Portland

97477

Clinical Site 158, Springfield

98125

Clinical Site 149, Seattle

98204

Clinical Site 148, Spokane

94598-5910

Clinical Site 160, Walnut Creek

33711-1141

Clinical Site 153, St. Petersburg

46290-1166

Clinical Site 154, Indianapolis

02111

Clinical Site 151, Boston

02114

Clinical Site 104, Boston

07003

Clinical Site 105, Bloomfield

08034

Clinical Site 136, Cherry Hill

07666

Clinical Site 114, Teaneck

37909-2686

Clinical Site 164, Knoxville

78240-1375

Clinical Site 140, San Antonio

00612

Clinical Site 201, Arecibo

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Parexel

INDUSTRY

lead

OcuTerra Therapeutics, Inc.

INDUSTRY